newsfilter
← Latest News
Earnings Call Transcripts·

Jefferies Global Healthcare Conference in London - GENEDX HOLDINGS CORP

  • Financial Performance:

    • Company is on track to deliver total volume growth near 30% for the year, with Q3 sample sessions up 25%.
    • Average Selling Price (ASP) grew mid-single digits sequentially in Q3, exceeding expectations by approximately $100; driven by a 4% improvement in genome collection rates (32% to 36%).
    • Gross margin profile remains solidified in the 30s range; the business is currently profitable.
    • Sequential business performance improved from Q1 through Q3, despite falling short of initial full-year expectations due to early-year mix shifts and volume volatility.
    • Current collection rates sit in the low 30s to 40s, with a long-term target of 70–80% as revenue cycle transformation matures.
    • Approximately 88% of commercial lives have active payer coverage for genome testing, though collection rates lag significantly behind coverage availability.
    • 62% of claim denials are attributed to administrative and procedural issues rather than medical necessity.
  • Guidance and Future Outlook:

    • Management expects another sequential ASP uptick of approximately $100 in Q4, driven by seasonal benefits, continued revenue cycle progress, and maturation of payer policies like Carillon and state Medicaid programs.
    • Revenue cycle transformation implementation is targeted for go-live in Q4 and Q1, which is expected to align sample submission sessions with final report volumes.
    • Long-term goal is to bridge the gap between coverage and collection rates, eventually driving revenue growth to converge with and exceed volume growth rates.
    • General pediatrics expansion is expected to contribute meaningfully to growth in 2027 and beyond, following a successful early ramp in late 2026.
    • NICU segment is projected to grow above the corporate average in fiscal 2026, though a major inflection point for utilization is anticipated further out.
  • Business Segments and Product Lines:

    • Genomics Services: Core business focused on pediatric rare disease diagnosis; experiencing a strategic shift from Exome to Genome sequencing, which is viewed positively for clinical outcomes despite early financial friction.
    • General Pediatrics: Commercial expansion included adding roughly 50 specialized sales reps in February; early indicators show strong new account activations and repeat order rates as the team educates physicians on 2025 AAP guidelines for global intellectual developmental delay.
    • NICU: Market is 100% cash/institutional pay, avoiding commercial adjudication risks; estimated addressable market is 250,000 tests/year, but current utilization remains in the mid-to-high single digits due to lengthy integration sales cycles.
    • Revenue Cycle Management (RCM): A multi-year transformation underway to automate documentation, prior authorization, and payer intelligence, moving away from manual "brute force" processes that previously slowed throughput.
  • Market and Competitive Landscape:

    • Addresses a $30 billion unmet clinical need affecting 1 in 10 Americans with rare diseases, surpassing the cancer market in total patient volume.
    • Strategic objective is to "move upstream" in the diagnostic journey, expanding testing access from a narrow cohort of 2,000 expert geneticists to the broader population of general pediatricians.
    • Market trend involves a natural migration from Exome to Genome-only testing, with physicians adopting the newer technology while largely remaining with GeneDx.
    • 8 out of 10 expert geneticists in the US already order Exome/Genome from GeneDx, leveraging 25 years of trust to expand into primary care settings.
    • Competition is minimal regarding the specific mission of ending the "diagnostic odyssey" for children, though the company faces challenges from disparate payer policies (nearly 1,000 unique rule sets).
  • Risks and Challenges:

    • Payer Policy Volatility: Disparate documentation requirements and medical necessity criteria across payers create significant friction, requiring continuous manual intervention and slowing the order-to-result cycle.
    • Operational Trade-offs: Early RCM improvements required slowing the testing process to secure prior authorization, degrading short-term customer experience and causing a divergence between sample submission and report completion rates.
    • Revenue Gap: A substantial disconnect exists between high payer coverage rates (~90%) and low actual cash collection rates (30–40%), which must be bridged to realize margin leverage.
    • Long Sales Cycles: particularly in the NICU sector, where embedding tests into hospital Standard Operating Procedures (SOPs) and protocols takes significant time and effort.
    • Cannibalization Risk: Management views this as a non-issue for the foreseeable future, citing the vast size of the addressable market and the distinct roles of generalists versus specialists.
  • Management Commentary and Tone:

    • Tone was confident and transparent, acknowledging early-year execution challenges while emphasizing strong underlying trends and sequential improvements.
    • Management expressed pride in the company's trajectory and the critical nature of its mission to reduce the average age of rare disease diagnosis from 14 years down to 5 years, with a goal of diagnosis at birth by the end of the decade.
    • Kevin (CEO) and the team demonstrated a pragmatic approach, accepting short-term volume/ASP volatility to secure long-term margin expansion and sustainable growth.
    • Confidence is high in the new RCM leadership and the ability to execute the technological transformation required to automate payer compliance.
  • Analyst Questions and Answers:

    • ASP Drivers: Q3 ASP growth was equally split between product mix and collection rate improvements; Q4 guidance relies on similar factors plus seasonal uplifts and policy maturation.
    • Volume vs. Sessions: The 3% divergence between volume and sample sessions in Q3 was a deliberate result of RCM holds; convergence is expected in Q4/Q1 once automated workflows launch.
    • Payer Coverage vs. Collections: Management clarified that coverage rates will eventually converge with collection rates, but current disparities are due to the complexity of 1,000+ unique payer rule sets rather than lack of coverage.
    • General Pediatrics Cannibalization: Analysts asked if new pediatric orders would cannibalize expert geneticist business; Management replied the market is too large for this to occur for decades.
    • NICU Inflection: Management noted no single "gating factor" for NICU growth; adoption varies by hospital system based on their willingness to rewrite protocols and embed new testing into high-intensity clinical workflows.
  • Other Key Points:

    • The average age of diagnosis for children with rare disease has already been reduced from 14 to 5 years over the last 11 years.
    • The company is investing in a "payer intelligence engine" using AI to scrape medical records and automate documentation, aiming to make the pre-analytical process frictionless for physicians.
    • Exome testing still comprises ~75% of the total portfolio but carries higher gross margins than Genome; the RCM transformation will eventually benefit the entire portfolio including multi-gene panels.
    • The company aims to move toward potential genomic newborn screening in the long term, a market of 3.6 million live births annually.
Company
GENEDX HOLDINGS CORP
Keywords
GENEDX HOLDINGS CORP